GILDGilead Sciences
−1.7% today · +40.6% over a year
5/10 A 1–10 summary of how an instrument compares with similar ones (same sector and region) by published rules. It describes today's data; it is not a price forecast. More in the glossary → «Balanced» — higher than 70% of the instruments we score
Stability: among the best of its peers. Dividend yield 1.94%.
Gilead Sciences (GILD) belongs to the Health care sector and is listed on Nasdaq; country: United States. Its market value is about €185.8B. Over the past 12 months the price changed by +40.6%, with an annualised volatility of 27% and a largest fall of 22%. The dividend has not been lowered for 11 years.
Smart Score
How it is scored →The Smart Score (1–10) describes how this instrument compares with its peers on published, rules-based measures of value, quality, trend, stability and dividend safety. It is not a forecast and not personal advice.
Compared with: Health care companies in USA (n = 337)
Current rating first published: · last recomputed · rating log
Factor scores
Percentiles within the peer group (100 = the best of its peers); dividend safety in points.
Main drivers
- Volatility (1 y)supports the score · better than 96% of peers
- Accrualssupports the score · better than 97% of peers
- Max drawdown (3 y)supports the score · better than 96% of peers
Red flags and notes
- Caution. Dividend Safety below 40 points. More in the glossary → Dividend Safety below 40 points.
- Caution. Net debt above 4× EBITDA or interest cover below 2×. More in the glossary → Net debt above 4× EBITDA or interest cover below 2×.
Our rules see a meaningful risk that this dividend is cut.
Price chart
Interactive chart by TradingView: exchange prices are delayed, crypto and currencies are live.
Key metrics
Valuation
- P/B
- 15.9
- P/S
- 6.7
- Free-cash-flow yield
- 6.6%
- Market cap (EUR)
- €185.8B
Profitability and debt
- Return on equity
- −22.3%
- Return on invested capital
- −6.6%
- Gross margin
- 79.9%
Dividends
- Dividend yield
- 1.94%
- 5-year dividend growth (per year)
- 3.0%
- Years without a lower dividend
- 11
Returns and risk
- 1 day
- −1.7%
- 1 month
- +15.7%
- 1 year
- +40.6%
- Volatility, 1 yr
- 27.0%
- Max drawdown, 1 yr
- −21.6%
- Beta
- 0.55
Ratios from SEC filings and end-of-day prices; returns are price changes without dividends.
Similar companies
Same sector and region, closest in market value.
| ABTAbbott | 6/10 | 2.8% | −9.5% |
|---|---|---|---|
| AMGNAmgen | 7/10 | 2.2% | 60.0% |
| PFEPfizer | 1/10 | 7.2% | 30.2% |
| TMOThermo Fisher Scientific | 9/10 | 0.3% | 24.1% |
| DHRDanaher | 7/10 | 0.7% | 8.3% |
| ISRGIntuitive Surgical | 6/10 | 0.0% | −19.0% |
| VRTXVertex Pharmaceuticals | 8/10 | 0.0% | 24.6% |
| MDTMedtronic | 9/10 | 2.9% | 13.3% |
News and filings
Insiders (SEC Form 4) 14 sales and 0 purchases in 6 filings since 16 Sep · net sold $9.3M
- Insiders (Form 4): net sale $5.3M (0 buys, 6 sales) 3 Nov 2026
- Insiders (Form 4): net sale $469K (0 buys, 1 sales) 16 Oct 2026
- Insiders (Form 4): net sale $469K (0 buys, 1 sales) 16 Oct 2026
- Insiders (Form 4): net sale $2.2M (0 buys, 2 sales) 2 Oct 2026
- Insiders (Form 4): net sale $433K (0 buys, 3 sales) 16 Sep 2026
- Insiders (Form 4): net sale $436K (0 buys, 1 sales) 16 Sep 2026
FactSEC EDGAR · trades by directors and officers, as filed; tap to see each filing- GILEAD SCIENCES, INC.: 10-Q — Quarterly report for the period ending 30 Sep 2026
A filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.SEC EDGAR · Filing · 30 Oct 2026
- GILEAD SCIENCES, INC.: 8-K — Results of operations
A filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.SEC EDGAR · Filing · 29 Oct 2026
- GILEAD SCIENCES, INC.: 10-Q — Quarterly report for the period ending 30 Jun 2026
A filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.SEC EDGAR · Filing · 6 Aug 2026
What the marks mean
- FactA filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.
- Media reportA headline from a named media outlet. We link to it and do not check it.
- RumourUnconfirmed: the headline itself hedges (“reportedly”, “sources say”, “in talks”), names no publisher, or comes from a news aggregator or an automated republisher.
Source: Filings: U.S. SEC EDGAR. The tone is scored automatically from the headline and can be wrong.
Score changes in the last 12 months
Every published rating and change, logged when it was published (EU Market Abuse Regulation).
Show the log: 9 entries
| Date | Event | Balanced | Growth · Income | Warnings | Price at publication |
|---|---|---|---|---|---|
| Rating change | 5/10 | 5 · 1 | — | Available with Invest Pro | |
| Rating change | 5/10 | 6 · 1 | — | Available with Invest Pro | |
| Rating change | 4 → 5/10 | 5 · 1 | — | Available with Invest Pro | |
| Rating change | 4/10 | 4 · 1 | — | Available with Invest Pro | |
| Rating change | 4/10 | 5 · 1 | — | Available with Invest Pro | |
| Rating change | 4/10 | 4 · 1 | — | Available with Invest Pro | |
| Rating change | 4/10 | 5 · 1 | — | Available with Invest Pro | |
| Rating change | 1 → 4/10 | 4 · 1 | removed: Yield trap, Payout above earnings | Available with Invest Pro | |
| First rating | 1/10 | 1 · 1 | Serious warning. Yield at least twice the peer median while the payout is not covered or debt is high. More in the glossary →Caution. Dividends exceed earnings or free cash flow. More in the glossary → | Available with Invest Pro |
Ratings are rules-based descriptions, valid until the next scoring run (about 06:20 and 21:50 UTC) and the same for every visitor.
Withdraw from contract here · EU consumers: 14 days to withdraw from a purchase.